Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by TheMadMonkon Oct 29, 2021 2:07am
1516 Views
Post# 34061921

Dan has been listening!

Dan has been listening!
So, after years of listening to a vocal group of disgruntled shareholders on this forum constantly complaining how Dan keeps diluting existing shareholders with share sales, it seems that Dan has come up with a solution.  I think Dan has been deliberately reducing the share price to these historically low levels for two reasons. First, it gives existing shareholders the opportunity to average down on their share price by adding (at in my opinion a great price for this stock).  Secondly, starting late spring and early summer 2022, millions of warrants will start to expire worthless thus enriching current shareholders stake in the company.
 
I hope that all those people who constantly complain about Dan will take the time to send him a thank you note.
 
Let's just pray that Dan doesn't do something stupid to increase the value of the share price in the next nine months.
<< Previous
Bullboard Posts
Next >>